To validate the direct binding of NEC-driving transcription factors at CRBN promoter region, we performed CUT&RUN assay followed by measuring enrichment by manual qPCR comparing non-neuroendocrine cancer H2023 cell lines and H2023 cells ectopically expressing the NEC-driving factors RPMA (5C3 clone) (Supplementary Figure S9B). The gene discussed is CRBN; the disease is neuroendocrine carcinoma.